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1. Introduction 
Human body is a complex chemical machinery, with as many as thousands of chemicals, 
namely proteins, carbohydrates, fats, etc. which exist all together. Every process in the body 
is some sort of chemical conversion that leads to movements, thought processes, feelings, 
pain and many more such complex as well as simple processes. The human body has also 
been provided with all the necessary chemical components or precursors, various enzymes 
and neurotransmitters for the balanced and proper functioning of all the life sustaining 
processes. Yet it so happens that some machineries or bioprocesses fail to function due to 
several exogenous or endogenous factors. Hence providing external aids, which we call 
“Drugs” or “Medicines”, becomes essential to restore the normal functioning. Drugs are 
nothing but chemical entities of synthetic or natural origin, which only modulate the body 
functions and have no new action on the body. This explanation however does not fit the 
chemotherapeutic agents used to treat parasitic infections, as they have no action on the 
human body, but, are targeted to the invading organism (Richard et al., 2009). The 
exogenous factors are varied right from parasitic invasion to some chemical entities which 
tend to disrupt the normal bodily functions. Hence repairing becomes mandatory, if bodily 
repair mechanism cannot match the rate of damage. The endogenous factor maybe faulty, 
functioning of organs, any genetic or congenital factor, over or under-production of some 
precursors which may lead to disorders. The classical examples of disorders due to 
endogenous factors are the neurodegenerative disorders like Parkinsonism and Alzheimer’s 
disease which arise due to the imbalance of acetylcholine and dopamine in the central 
nervous systems. Though there is no cure for these disorders but drugs and therapies have 
been developed to prolong and improve the quality of life. (Moore et al., 2005; Cummings et 
al., 1998). Hence, drug discovery can also called as patient-oriented science meant for 
improving the quality of life by developing newer and safer agents. 
Drug discovery plays an important role for the growth of any pharmaceutical industry and 
also to the society, as newer and safe drugs are launched in the market with the view to 
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improve the therapeutic value and safety of the agents. The pharmaceutical industry has 
consistently shown that it can discover and develop innovative medicines for a wide range 
of diseases (Ratti & Trist, 2011). The revenue that flows in with the invention of newer 
agents has always been the motivation for the industry to keep up the pace and keep abreast 
with the ever increasing demand for medicines.  
The advent of molecular biology, along with numerous developments in the screening and 
synthetic chemistry technologies, has allowed learning both, the knowledge about the 
receptor and random screening to be used for drug discovery. Today, more or less all 
pharmaceutical industries follow common techniques for discovering drugs. These include 
cloning and expressing human receptors and enzymes in formats that allow high-
throughput screening and the application of combinatorial chemistry. Thus, random 
screening can now be done with libraries sufficiently large and diverse to have a relatively 
high probability to find a novel molecule. These libraries are possible because they can be 
generated by the techniques of combinatorial chemistry (Black, 2000).  
Drug research, as we know it today, began its career when chemistry had reached a degree of 
maturity that allowed its principles and methods to be applied to the problems outside of 
chemistry itself and when pharmacology had become a well-defined scientific discipline in its 
own right. By 1870, some of the essential foundations of chemical theory had been laid. 
Avogadro's atomic hypothesis had been confirmed and a periodic table of elements 
established. Chemistry had developed a theory that allowed it to organize the elements 
according to their atomic weights and valencies. There were set of theories of acids and bases. 
In 1865, August Kekulé formulated his pioneering theory on the structure of aromatic organic 
molecules (Drews, 2000a and 1999b). During the first half of the 20th century drug research 
began shaping up and was developed by several new technologies, which carried the drug 
discovery process to its best. Biochemistry also had tremendous influence on drug research in 
many ways. The concept of targeting enzymes as drug targets came in to existence, that led to 
the designing of enzyme substrates which acted either as inhibitors or showed their action by 
modifying various feedback mechanisms. (Meidrum & Roughton, 1933). 
Table 1 shows some important discoveries in the field of medicine, right from 19th century to 
21st century 
 
Sr. no Year of Discovery Drug Name Category 
1. 1806 Morphine Hypnotic agent 
2. 1899 Aspirin Analgesic and Anti-pyretic agent 
3. 1922 Insulin Anti-Diabetic agent 
4. 1928 Penicillin Antibiotic 
5. 1960 Chlordiazepoxide Tranquillizer 
6. 1971 L-dopa Anti-Parkinson agent  
7. 1987 Artemisinin Anti-malarial agent 
8. 1998 Sildenafil  Erectile Dysfunctioning treatment 
9. 1999 Celecoxib, Rofecoxib Selective COX-2 inhibitors 
10. 1999 Zanamavir, 
Oseltamivir 
Anti-influenza agents 
11. 2001 Imatinib Leukemia treatment 
Table 1. Important discoveries in medicine 
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The present day drug discovery process is a very time consuming process as it takes at least 
14-16 years of research for a molecule to completely transform into a drug. There are several 
100 basic research projects, before desired molecule is discovered. But, this molecule is not yet 
ready to be called as a drug. After the pre-clinical establishment and confirmation of its action 
and toxicity data, the FDA approves the candidate for clinical studies. The Clinical phase of the 
study takes at least 6-8 years, before the candidate can be launched in to the market. After 
this stage, the molecule is said to have transformed from a molecule to drug. Even after the 
launch of the drug in the market, the post-marketing surveillance and pharmacovigilance 
program is being carried out to find out whether any new adverse reaction or 
incompatibilities towards other agents, when given as combination therapies. (Congreve, et al., 
2005). Figure 1 depicts the entire drug discovery process with the tentative timeline. 
 
Fig. 1. Drug discovery and development process (Lombardino and Lowe, 2004).  
2. Drug discovery process 
Drug discovery process basically is a patient oriented science, where researchers strive to 
improve the existing drugs or invent a totally new chemical entity, which should be ideally 
more potent than any existing drug of a similar category. If not, then at least it should be 
safer than those existing. This process is a very time consuming and expensive activity, 
calling for the expertise of many eminent researchers. It takes nearly 12-14 years of 
exhaustive research and a huge amount of financial investment for the discovery of a single 
drug. Right from the chemical synthesis to its clinical development and finally formulating 
it to a suitable form. Failure at any stage would mean a huge loss for the company. Hence, a 
lot of planning is required even before the project is underway. Recently, with the use of 
technology the process is becoming a less risky business, because of the ability of the 
computers to predict the possible outcomes. This will surely reduce the efforts in fruitless 
directions (Augen, 2002). 
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The following paragraphs shall discuss the various stages of drug discovery process. 
2.1 Identification of biological targets 
The human body functions normally by the virtue of the biochemical process which go on, 
producing all the necessary chemicals required for numerous functions to undergo 
smoothly within the body. Many of these processes are regulated by the enzymes and the 
endogenous effector molecules via their respective receptors. A diseased state, may hence, 
be identified by, either the abnormal biochemical functioning or, over or underproduction of 
some of the intermediates. Hence , the most important and most common biological targets 
for drug discovery are either enzymes regulating the biochemistry or the receptors through 
which many hormones and endogenous effectors show their response. For example, 
inhibition of human dihydrofolate reductase, by methotrexate, brought under control the 
growth of tumour in humans (Borsa and Whitemore, 1969). Similarly, blocking of the beta-
adrenoceptors in the cardiac muscles was found to reduce the hypertensive state (Pearson, 
et al., 1989). Another type of biological targets are nucleic acids. Though they are rarely 
targeted as compared to those mentioned above, yet they are important targets. 
(Overington, et al., 2006). 
2.2 Validation of biological targets 
Once the target is identified, it becomes absolutely necessary to confirm, that the correct 
target has been identified. The use of reliable and suitable animal models and the latest 
techniques in gene targeting and expression are all essential to the validation process. 
(Abuin, et al., 2002). Validation also helps researchers to identify any secondary target that 
the drug may bind to, which may lead to any sort of unwanted or adverse reaction. Ideally 
the drug candidate should be such that it binds to a single target only, but this seldom 
happens. Thus, binding to other targets, apart from the correct target leads to unwanted 
pharmacological actions. These cannot be completely avoided. It can be minimized to 
negligible extent. (Marton, et al., 1998). G-protein coupled receptors (GCPRs) are the most 
common and the major targets where a drug binds. Hence, over 30% of drugs in market are 
modulators of GPCR. The quantitative polymerase chain reaction (qPCR) analysis is one of 
the techniques used to measure the mRNA expression on the receptor. (Wise, et al., 2002).  
2.3 Lead structure search 
A lead compound is the one that has basic structural requirements for exhibiting the desired 
action. This means that, a lead compound has many structural spaces for further 
development of the structure, to give a compound with further enhanced action. High-
throughput screening is a technique, which helps to identify the lead compound out of the 
many synthesized compounds or those compounds which are collected from the natural 
source. Hence, it becomes utmost important to identify the lead compound, as this forms the 
basis for further development of the molecule(s). (Bleicher, et al., 2003). Figure 2 illustrates 
the design cycle for lead search. The various other techniques involved in lead identification 
are virtual screening, informatics, pharmacaphore mapping, High  throughput docking, 
NMR-based screening and chemical genetics. (Xue and Bajorath, 2000).  
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Fig. 2. The Design cycle describes the optimization of a lead structure to one or several 
development candidates. 
2.4 Lead optimization 
As soon as the lead structure is identified, the next step is to optimize the same. Here, the 
chemists in close collaboration with the pharmacologists will carefully study the structure-
activity relationship and will synthesize such other derivatives, so as to get a compound 
with the best possible desired activity. The various other approaches for lead optimization 
are Structure-Based Drug Design (SBDD), Quantitative Structure-Activity Relationship 
(QSAR) and Computer-Assisted Drug Design (CADD). All such approaches generate a huge 
amount of data, so as to assist the chemist in optimizing the lead to the best possible 
structure, with best possible desired action. These aforementioned approaches shall be dealt 
in detail in the later part of the chapter. (Joseph-McCarthy, 1999 & Ooms, 2000). Figure 3 
represents the design cycle for lead optimization and drug development. 
 
Fig. 3. Design cycle for lead optimization 
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2.5 Preclinical studies 
The main objective of preclinical studies is to ascertain the safety of the newly developed 
molecule. A newly developed molecule is never permitted to be tested on the human body, 
unless supported by a confirmed data about the pharmacology and toxicology of the 
molecule which is, based on animal studies is obtained. This phase, generally deals with 
elucidating the mode of action the molecule and getting an idea about the pharmacokinetics 
(PK) and pharmacodynamics (PD) of the molecule. However, the most important is the 
toxicological data obtained from the animal study, which gives the rough estimate about the 
possible adverse reactions that may be likely to be seen during the course of the therapy. 
These are carried out in two stages, in-vitro studies and in-vivo studies. The in-vitro studies 
make use of different cell-lines and tissue preparations. The in-vivo studies are performed 
on the live animals and are observed the changes in the animal’s behavior. (Caldwell, et al., 
2001 & Smith, and van de Waterbeemd, 1999).  
2.6 Clinical trials 
The next stage after preclinical studies is the clinical studies, actual testing of the molecule 
in the human volunteers. This phase allows to assess the safety and efficacy of the new 
molecule. This phase also allows to gather information about the toxicological effects in the 
human body, as seldom the toxicity shown by animals, cannot be always directly 
correlated to the humans. Before the start of this stage, the innovator should file an 
application, namely, “Investigational New Drug (IND)”, as the FDA approves based on 
the preclinical data, the innovator can proceed for clinical studies. This stage consists of 
three phases, phase 1, phase 2, phase 3 and the phase 4 studies are carried out after the 
drug has been launched in to the market.  
Phase 1 studies are usually carried out on healthy human volunteers and on a small group of 
people. This phase evaluates the safety, tolerability and PK and PD of the new molecule. 
Phase 2 studies are generally carried out on a small population with the target disease. In 
this phase, the drug’s efficacy and safety, metabolism and PK are evaluated in a diseased 
human body.  
Phase 3 studies are extensive and multiple site studies. This phase, covers a large group of 
individuals with target disease. This phase basically is a therapeutic confirmatory phase, as 
all the parameters studied in the phase 2 of the study are confirmed in this phase. This phase 
may take somewhere about 3-6 years to complete. After this phase is successfully 
completed, the company files the “NEW DRUG APPLICATION (NDA)”to the FDA. Once 
the FDA issues an approval to the company, based on their data compiled from the clinical 
trials, the drug can be launched in the market.  
Phase 4 (Post-Marketing survilience) studies are carried out, after the drug has been 
launched into the market. The company continues its monitoring of the drug. The 
rationale behind this phase is to check for any new adverse or serious reaction which was 
not detected in the earlier phases and may be observed in this phase. If so happens that 
some serious adverse reaction is observed, the company may withdraw the drug from the 
market. (Singh, et al., 2011). 
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2.7 Formulations for clinical studies  
The formulations for clinical studies are usually prepared as capsule dosage form, as it is 
easy for formulation and also easy for administration. Apart from this advantage, there is 
another key factor to be considered while formulating a trial batch, as the drug itself has not 
been tested in humans, any untoward action can be directly ascertained to the drug in the 
absence of any excipients. Capsules, unlike the tablets can be formulated without any or 
minimal excipients. Liquid dosage forms may also be formulated, provided the drug is 
water-soluble, for the ease of preparation and water being the safest medium. Formulations 
should be properly tested for its stability and must be stable at least for the period the trials 
are underway. The other reason for choosing simple formulations is to avoid any time lag, 
as the process of trials itself is lengthy. Any more delay, may further lead to the delay in 
marketing the drug.  
3. Computer-aided drug design 
Computers, have found their way in every field of science and technology today. The boon 
of computers is that a large number of calculations and observations can be done in no time. 
Drug discovery and designing is no exception to this generalization. Drug designing has 
received a many fold face-lift by the virtue of computer software dedicated to the designing 
of ligands and identifying the biological targets. Computer generated structures serve to be 
good predictive models for the evaluation of biological activity.  
A drug exhibits its action when it binds to its biological target, usually receptors. Receptors 
are nothing but proteins with active sites for the binding of ligands. Hence, in order to 
design a good ligand, it becomes necessary to know the structure of such receptors and to 
identify their active sites accurately. The two important aspects involved in predicting 
molecular-interactions in computer-aided drug design (CADD) are development of 
pharmacophore-based and molecular docking and scoring techniques. Computerized 
structure of the known proteins is based on the experimental data present in various 
literatures and protein data banks. With this, it is possible to deduce the 3D structure of the 
all the known proteins with the help of sequence homology approach. Hence, these 
hypothetical proteins behave more or less like the real proteins in their native biological 
environment (Taft, et al., 2008). Recently, many computer-assisted models are being 
developed and several thousand candidates are being screened for various activities using 
these models. The methods of choice for this purpose are computer programs that 
superimpose molecules by a flexible alignment to derive pharmacophoric patterns and/or 
quantitative structure-activity relationships, dock molecules to the surface of a protein 3D 
structure or to a hypothetical pseudoreceptor, or construct new ligands within a predefined 
binding site  (Klebe, 1995 & Kubinyi, 1998a).  
Different molecular property fields, such as electrostatic, steric, hydrophobic, hydrogen 
bond acceptor and donor fields, as well as their weighed combinations, have been used to 
achieve a fully automated alignment of the molecules. (Mestres, et al., 1997). The process of 
docking process involves the prediction of ligand conformation and orientation within a 
targeted binding site. Docking is basically performed for accurate structural modelling and 
correct prediction of the biological activity. Figure 5 depicts an image witch is generated by 
docking studies (representational purpose only) 
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Fig. 5. Representation of molecular docking (Bo, et al., 2010).  
 
Type of study Software 
programme 
Innovator 
Protein-Ligand docking AUTODOCK The Scripps Research Institute 
 COMBIBUILD Sandia National Labs 
 DOCKVISION University of Alberta 
 FRED OpenEye 
 FLEXIDOCK Tripos 
 FLEXX BioSolveIT GmbH 
 GLIDE Schrödinger GmbH 
 GOLD CDCC 
 HINT! Virginia Commonwealth 
University 
Protein-Ligand & Protein-
Protein docking 
DOCK UCSF Molecular Design 
Institute 
 GRAMM University of Kansas 
 ICM-DOCk MolSoft LLC 
Table 2. lists the various computer programmes used for docking studies. (Structure based 
drug design and molecular modelling, http://www.imb-
jena.de/~rake/Bioinformatics_WEB/dd_tools.html) 
4. Molecular modelling and drug design 
Theoretical studies of biological molecules permit the study of the relationships between 
structure, function and dynamics at the atomic level. The entire process is about simulation 
of the biological processes and quantum mechanical calculation based on the principles of 
chemistry and physics.  
4.1 Molecular mechanics- force field (Potential energy function) 
Current generation force fields (or potential energy functions) provide a reasonably good 
compromise between accuracy and computational efficiency. They are often calibrated to 
experimental results and quantum mechanical calculations of small model compounds. 
Their ability to reproduce physical properties measurable by experiment is tested; these 
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properties include structural data obtained from x-ray crystallography and NMR, dynamic 
data obtained from spectroscopy and inelastic neutron scattering and thermodynamic 
data. (MacKerell, et al., 1995). 
The molecular structures, properties and energies of a molecule are better understood 
through the use of the mechanical molecular model. This model involves the development 
of a simple molecular mechanics energy equation representing the sum of various energy 
interaction terms comprised of bonds, angles, torsions of both bonded and non-bonded 
atoms. Force fields the model serves as a simple descriptor for vibrations in molecules. The 
concept of force fields is now widely employed as one of the simplest tools in molecular 
modeling. 
Force fields are fundamentally important in de novo drug design programs, in 
pharmacophore mapping, and represent the “scoring functions” in many docking 
programs. As scoring functions, force fields are used to rank “ligand poses” obtained by a 
docking algorithm, or in de novo ligand design programs to suggest placement of 
fragments in the sites in the enzyme with the highest binding affinity. In all these 
applications, force fields are mainly used to compute the interaction energy between the 
protein and the ligand as pair-wise interaction potentials consisting of van der Waals and 
electrostatic interactions, in addition to H-bond energy between the ligand and the 
enzyme. (Pissurlenkar, et al., 2009). 
4.2 Energy minimization methods 
The goal of energy minimization is to find a route from an  initial conformation to the 
nearest minimum energy conformation using the  smallest number of calculations possible. 
NMR and X-ray crystal structures tend to have high energy interactions like Pauli 
repulsions. That is because the methods to retrieve molecular structures are not perfect and 
especially in x-ray-structures there are crystal contacts, which lead to a compaction of the 
molecules. Moreover, hydrogen atoms are added to relatively arbitrary positions near their 
neighbors. Thus, there are atoms lying too close together so that the Pauli repulsion 
outweighs the dispersion attraction and the energy is raised high above natural energy 
levels. These high energy interactions lead to local distortions which result in an unstable 
simulation. They can be released by minimizing the energy of the structure before starting a 
run. The minimization results in a structure with energy near the lowest possible energy the 
system can have. (Leach, 2001 & Höltje, et al., 2003) 
4.3 Conformational analysis 
Conformational analysis deals with the computation of minimal energy configurations of 
deformable molecules and docking involves matching one molecular structure to the 
receptor site of another molecule and computing the most energetically favorable 3-D 
conformation. (Go and Scherga, 1970).  
4.3.1 Systematic search (Scheraga, et al., 1992) 
Due to the convoluted nature of the potential energy surface of molecules, minimization 
usually leads to the nearest local minimum, and not the global minimum. To scan the 
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potential surface with some surety of completeness,  systematic, or  grid,  search  procedures 
have  been developed. The following protocol is used for the same, 
1. Rigid geometry approximation 
2. Combinatorial  nature  of  the  problem 
3. Pruning  the  combinatorial  tree 
4. Rigid  body  rotations 
5. Exploitation  of rings 
6. Conformational  clustering  and families 
7. Conformational analysis 
4.3.2 Monte Carlo simulation 
The Monte Carlo simulation is based on statistical mechanics and generates sufficient 
different configurations of a system by  computer simulation to allow the desired structural, 
statistical, and thermodynamic  properties to be  calculated as a weighted average of these 
properties over these configurations. A useful application  has combined Monte Carlo  
sampling with  variable  temperatures  (simulated  annealing)  to  optimize  the  docking  of  
ligands into  active  sites. (Allen, & Tildesley, 1989) 
4.3.4 Molecular dynamic simulation 
Molecular dynamics is a deterministic process based on the simulation of molecular motion 
by solving Newton’s equations of  motion for each atom and incrementing the position and 
velocity  of  each atom by  use of  a small time increment. Molecular dynamics simulations 
represent another technique to sample configuration space, based on the aforementioned 
principle. Combined with the use of “reasonable” temperatures (a few hundreds or 
thousands of degrees), this means that only the local area around the starting point is 
sampled, and that only relatively small barriers (a few tens of a kJ/mol) can be overcome. 
Different (local) minima may be generated by selecting configurations at suitable intervals 
during the simulation and subsequently minimizing these structures. MD methods use the 
inherent dynamics of the system to search out the low-energy deformation modes and they 
can be used for sampling the conformational space for large confined systems (Tuckerman, 
& Martyna, 2000).  
4.4 Structure-based and Ligand-based drug design approaches 
Structure-based drug design by the use of structural biology remains one of  the most logical 
approaches in drug discovery. It combines information from several fields: X- ray 
crystallography and/or NMR, molecular modeling, synthetic organic chemistry, QSAR, and 
biological evaluation (Marrone, et al., 1997). Figure 6 shows the schematic process. 
Many of the naturally occurring molecules are found to be very potent, and also the 
endogenous chemicals give a lot of information for drug designing. The use of such ligands 
to generate and design newer ligands is called ligand-based drug design. Many a times 
straightforward design process starts from conformationally restricted natural receptor 
ligands, such as from polypeptides or proteins. Some of the applications of structure and 
ligand based drug design are Renin and protease inhibitors, β-lactamase inhibitors, reverse 
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transcriptase inhibitors, angiotensin converting enzyme inhibitors, HIV-1 integrase 
inhibitors and many more. (Kubinyi, 1998b). 
 
Fig. 6. Representation of structure based drug design. 
4.5 3D pharmacophore modeling 
Various conformations of a range of ligands that all act at the same receptor site can provide  
significantly more  information than just a single ligand structure. With a sufficiently broad 
range of ligands, it is often possible to generate a pharmacophore model  of  the receptor 
site. The advantage of such a pharmacophore model is that smaller,  non-peptide molecules  
that  might have improved  stability and bioavailability over their peptide counterparts  can 
be designed, relative easy and certain amount of confidence towards getting successful 
outcome. (Nielsen, et al., 1999).  
4.6 Rational drug design 
The Concept of rational drug design simply lies in logical reasoning before designing any 
therapeutic agents. For example, to prepare any competitive inhibitor of a particular target, 
the logic of predicting the structure is to simply design an molecule with similar structural 
features exhibited by the endogenous agent or by closely examining the active binding site. 
Close examination of the active site gives many hints about the interacting amino acid 
residues, so it becomes simple to predict the nature and type of substituents and the 
favorable position in the molecule, which will favor better binding. 
4.6.1 Design of enzyme inhibitors 
Almost every biochemical process in the human or parasite is catalyzed by various enzymes 
of diverse function. As a result enzymes have always been the hot target for designing new 
drugs for various clinical conditions. The most popular example is the inhibition of 
acetylcholinesterase enzyme in the human brain is one of the most successful targets to treat 
the symptoms of Alzheimer’s disease. The first step in designing an agent to inhibit an 
enzyme is to study thoroughly the structure and the binding site/pocket of the endogenous 
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substrate. It is always favorable to design the new agent based on the structural 
requirements into the pocket of the catalytic site of the enzyme based on endogenous 
substrate or agents already designed for the purpose. The binding of the inhibitor should be 
more preferred or favourable than the endogenous substrate, in order to develop a 
successful inhibitor and at the same time care should also be taken so as to not develop an 
irreversible inhibitor, this may permanently destroy the enzyme. Popular drugs designed in 
this fashion are the HIV-1 protease inhibitors, thrombin inhibitors, neuraminidase inhibitors 
and many more. (Prasad, et al., 1996, Kimball, 1995 & Wade, 1997). 
4.6.2 De Novo Ligand design 
Designing of novel chemical structures that are capable of interacting with a receptor of 
known structure using methodology that is much more reliable, is what we call De Novo 
Ligand design. Techniques for the design of novel structures to interact with a known 
receptor site are becoming  more and more available and have shown a lot of promise  for 
the future. The thorough understanding of the various classes of chemicals interacting with 
the particular receptor, can give a lot of information to design novel agents by replacing the 
scaffold with another one to have similar sort of interaction and at the same binding site. 
(Klebe, 2000 & Bohm, and Stahl, 2000).  
5. Quantitative Structure Activity Relationship (QSAR) 
QSAR correlate, within congeneric series of compounds, affinities of ligands to their binding 
sites, inhibition constants, rate constants, and other biological activities, either with certain 
structural features (Free Wilson analysis) or with atomic, group or molecular properties, 
such as lipophilicity, polarizability, electronic and steric properties. (Kubinyi, 1995). 
5.1 Parameters 
5.1.2 Hydrophobicity 
Molecular recognition depends strongly on hydrophobic interactions between ligands and 
receptors. Hydrophobicities of solutes can readily be determined by measuring partition 
coefficients designated as P. Partition coefficients are additive-constitutive, free energy-
related properties. Log P represents the overall hydrophobicity of a molecule, which 
includes the sum of the hydrophobic contributions of the "parent" molecule and its 
substituent. Whole-molecule approaches use molecular properties or spatial properties to 
predict log P values. (Taylor, 1990 & Kellogg, et al., 1992). 
5.1.3 Electronic 
Electronic attributes of molecules are intimately related to their chemical reactivities and 
biological activities. The extent to which a given reaction responds to electronic perturbation 
constitutes a measure of the electronic demands of that reaction, which is determined by its 
mechanism. Hammett employed, as a model reaction, and determined their equilibrium 
constants Ka, which led to the definition of an operational constant, called the Hammett’s 
constant σ, It is a measure of the size of the electronic effect for a given substituent and 
represents a measure of electronic charge distribution in the parent nucleus. (Hammett, 1966).  
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5.1.4 Steric effects 
The quantitation of steric effects is complex and challenging in all other situations, 
particularly at the molecular level. Sterics are of utmost importance in ligand-receptor 
interactions as well as in transport phenomena in biological systems. The first steric 
parameter to be quantified was Taft’s Es constant. One of the most widely used steric 
parameters is molar refraction (MR). MR is generally scaled by 0.1 and used in biological 
QSAR, where intermolecular effects are of primary importance. The failure of the MR 
descriptor to adequately address three-dimensional shape issues led to Verloop's 
development of STERIMOL parameters, which define the steric constraints of a given 
substituent along several fixed axes. (Taft, 1956, Tute, 1990 & Verloop, 1987). 
5.2 Quantitative models 
All QSAR analyses are based on the assumption of linear additive contributions of the 
different structural properties or features of a compound to its biological activity, provided 
that there are no nonlinear dependences of transport or binding on certain physicochemical 
properties. (Kubinyi, 1997). 
5.2.1 Hansch analysis 
The linear free-energy-related Hansch model, also sometimes referred to as the 
'extrathermodynamic approach. The model makes use of log P and Hammett constant. The 
equation of this model is as follows  
logl/C=a(logP)2+blogP+cσ+... +k 
where P is the partition coefficient, σ is the Hammett  electronic  parameter, k is a constant 
term, and a, b, c are the regression coefficient. This equation is built on the concept that the 
permeation of drug in the cell, and the binding of the drug are function of its lipophilicity, 
electronic properties and other linear free-energy related properties. (Hansch, and Leo, 1995). 
5.2.2 Free Wilson analysis 
Free-Wilson approach is truly a structure-activity-based methodology because it 
incorporates the contributions made by various structural fragments to the overall biological 
activity. The equation of this model is as follows  
  
Where BA stands for biological activity, Xj is the jth substituent, which carries a value 1 if 
present and 0 if absent, aj represents the contribution of the jth substituent to biological 
activity. (Franke, 1984 & Free, and Wilson, 1964). 
5.3 Other QSAR approaches 
In this section, we discuss some of the most widely used 3D-QSAR techniques. The review 
by Evans et al on 3D-QSAR is worth reading for further understanding (Verma, et al., 2010). 
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5.3.1 Hologram Quantitative Structure Activity relationship (HQSAR) 
Hologram QSAR is a unique QSAR method. This method does not require the exact 3D 
information for the ligands. In this technique, the molecule is hashed to a molecular 
fingerprint that encodes the frequency of the occurrence of various molecular fragment 
types. In simpler words, the fragment size controls both the minimum and maximum length 
of the fragments to be included in the hologram fingerprint. Molecular holograms are 
produced by generating all the linear and branched fragments, which range in size from 4 to 
7 atoms. (Suh, et al., 2002).  
5.3.2 Comparative Molecular Field Analysis (CoMFA) 
Comparative molecular field analysis (CoMFA) is a promising new approach to structure-
activity correlation. Work on CoMFA began in at 70’s and is one of the more famous 3D 
QSAR methods. It provides steric and electrostatic values in addition to ClogP values. 
ClogP means the hydrophobic parameters of the ligands. (Cramer, et al., 1988 &Wold, et 
al., 1984). 
5.3.3 Comparative Molecular Similarity Indices Analysis (CoMSIA) 
Comparative Molecular Similarity Indices Analysis (CoMSIA) is known as one of the newer 
3D QSAR methodology. This technique is most commonly used in drug discovery to find 
the common features that are important in binding to the relevant biological receptor. In this 
technique, both steric and electrostatic features, hydrogen bond donor, hydrogen bond 
acceptor and hydrophobic fields are considered. (Malinowski, and Howery, 1980). 
6. Combinatorial chemistry and High-Throughput Screening (HTS) 
Combinatorial Chemistry is a technology for synthesizing and characterizing collections of 
compounds and screening them against various diseases. It was primarily used for the 
synthesis of peptide and oligonucleotide libraries. Many compounds discovered 
combinatorially have at least entered preclinical or clinical trials. That's some proof of the 
value of combinatorial chemistry. But the bottom line is that many researchers in academia, 
industry, and government already recognize it as an integral component of the drug 
discovery repertoire. (Borman, 2002). 
High-Throughput Screening (HTS) a high-tech approach for drug discovery, is more and 
more gaining popularity among industrial researchers as well as students doing their 
post-graduate and/or doctorate research projects. It is basically a process of screening and 
assaying huge number of biological modulators and effectors against selected and specific 
targets. The principles and methods of HTS find their application for screening of 
combinatorial chemistry, genomics, protein, and peptide libraries. The main purpose or 
goal of this technique is to hasten the drug discovery process by screening the large 
compound libraries with a speed which may exceed a few thousand compounds per day 
or per week. For any assay or screening by HTS to be successful several steps like target 
identification, reagent preparation, compound management, assay development and 
high-throughput library screening should be carried out with utmost care and precision. 
(Martis, et al., 2011a). 
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7. Conclusions 
Many more approaches like metabolomics, genomics, proteomics also compliment well with 
the other techniques so that more target specific agents can be discovered with more 
accuracy. The review on metabolomics shall explain more in detail (Martis, et al., 2011b). 
Drug discovery is yet more to be explored, even more than that explored till date. The 
findings of the human genome project has added more understanding to the target 
identification. Nature has made all the provisions for curing a disease or disorder, human 
efforts of finding is what is required. Exploring natural sources which is ill-explored should 
be effective done as nature is source of countless chemicals which could lead to a successful 
drug candidates. 
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